TEL AVIV, Israel--(BUSINESS WIRE)--Feb. 19, 2004--Tissera, Inc. (OTCBB:TSSR - News), a biotechnology company dedicated to developing novel tissue precursor regeneration technologies to address a myriad of fatal illnesses where an organ transplantation is necessary announced that Dr. Vicki Rabenou, MD has been appointed CEO.

Prior to joining Tissera, Dr. Rabenou was the President and CEO of the Rad BioMed Incubator and Board Member of each company in the incubator. There, Dr. Rabenou was responsible for identifying and promoting innovative and promising early stage biomedical companies.

Dr. Rabenou is a graduate of the Hadassah Medical School of the Hebrew University in Jerusalem with training in Obstetrics and Gynecology.

"I am very enthusiastic about my new position and am looking forward to fulfilling the company's mission to develop new sources for tissue and organ transplantation. We face a great challenge in helping millions of sufferers who are forced to wait years for a suitable organ donor because there are no alternatives. Many people die waiting, while the lucky ones, who finally get a matching donor and undergo a successfully organ transplant, are kept on high doses of immunosuppressive drugs which leave them vulnerable to infectious diseases and at a high risk for cancer. We are here to change that and offer these individuals new hope," said Dr. Rabenou.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed at the Weizmann Institute of Science in Israel led by Professor Yair Reisner. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."